Market Playground

Generex Biotechnology Corporation (OTC:GNBT): AE37 Update Unable to Move Share ... Market Playground By VFC's Stock House Generex Biotechnology Corporation (OTC:GNBT) subsidiary Antigen Express provided an update on its cancer immunotherapy AE37 last week, but the news – which was the announcement of positive interim results – failed to move the GNBT ... and more »

Source:
http://news.google.com/news?q=biotechnology&output=rss

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

International Stem Cell Corporation (OTCBB: ISCO) announced today that Kenneth Aldrich, Chairman, will be presenting at the 2011 Southern California Investor Conference on Monday, August 29, 2011 at 1:30 p.m. Pacific (4:30 p.m. Eastern). The conference takes place at The Island Hotel in Newport Beach, California.


The Southern California Investor Conference is the only conference focused exclusively on the wealth of exciting growth companies from Southern California. The annual one-day conference features more than 35 companies from the region presenting to attendees from throughout the nation. The conference is open to the public and investors can find a list of 2011 presenting companies and registration information at http://www.CaliforniaStocks.com


A webcast of the International Stem Cell Corporation presentation will be accessible online at http://events.powerstream.net/002/00271/20110829_SCIC_T2/ or from the link on the Company's web site at http://www.internationalstemcell.com. An archived version will be available for 30 days.


About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.


To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.


International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

Novinite.com

WikiLeaks: Ambassador Warlick: Bulgarian Government Walks Tight Rope on GMOS Novinite.com (SBU) Summary: A draft law that would bring Bulgaria's current restrictive biotechnology regime into EU compliance has been seized upon by anti-GMO groups. As a result, as a tactical response, the government is proposing, as a supplement to the draft ... and more »

Source:
http://news.google.com/news?q=biotechnology&output=rss

Franklin is a patient with spinal cord injury. This video is the experience of Franklin R. who underwent stem cell treatment to improve his condition after an accident that left him paraplegic.

Visit link:
Spinal Cord Injury - Stem Cell Therapy

Sunjay Kaushal USA river-valley.tv

More:
Cardiac Stem Cells in End-Stage Human Failing Hearts: Are they functional?

Medicenter, a Stem Cells clinic in Guatemala, Central America. Mr. Gemperline had a stem cell transplantation

Go here to read the rest:
Stem cell therapy in Guatemala - (closer than China)

Amniotic Fluid Based Stem Cell Injections are being offered at Preferred Pain Center in Arizona. The injections offer an opportunity to harness the body's regenerative potential and exponentially increase it: 1) Anti-inflammation 2) Hyaluronic Acid 3) Stem Cells 4) Non-steroidal, non-embryonic treatment Pain relief plus potential regeneration of cartilage and soft tissues such as rotator cuff and ligaments.

Read more:
Regenerative Medicine With Stem Cell Therapy Injections at an Arizona pain clinic (602) 507-6550

Japanese scientists from Kyoto University, led by Professor Shinya Yamanaka and American researchers from the University of Wisconsin, led by James Thomson managed to create multifunctional stem cells from human skin. Earlier, generation of stem cells required cloning or use of human embryos.

Read more:
Stem cells acquired from human skin

Recent research from Scotland reinforces the longstanding medical opinion that vitamin D deficiency leads to a significantly increased risk of bone fractures.

Among people with hip fractures referred to the Scottish fracture liaison service, 98 percent test positive for serious deficiencies in vitamin D. Supplementation with the vitamin, on the other hand, significantly reduces the risk of repeat fractures.

"Taking a supplement can make a difference quite quickly," said Stephen Gallacher, head of the liaison service. "Bone density can increase by 20 percent in a few months with enough vitamin D."

"We have found we can reduce fractures by something like 30 to 50 percent. It is our belief that we can significantly reduce the risk of fractures in the population by giving people anti-osteoporosis therapy and vitamin D supplements."Read more...

Cardiofy Heart Care Supplement

Source:
http://feeds.feedburner.com/integratedmedicine

The Guardian (blog)

The Cleverness Of The Apes (GALLERY) Global Animal (GREAT APES/ANIMAL SCIENCE) In “Rise of the Planet of the Apes,” experiments with genetic engineering lead to an incredibly intelligent species of ape. In reality, these non-human primates are in fact very smart and have better, faster memories than we ... Movie Review: Rise of the Planet of the ApesWishaw Press Rise of the Planet of the Apes – 'Human, all too human'The Guardian (blog) all 118 news articles »

Source:
http://news.google.com/news?q=genetic-engineering&output=rss

Sunday Observer

2nd International Festival of Biotechnology - India: Sunday Observer Nalanda College, Colombo won first place at the 2nd International Festival of Biotechnology held at the CMS Rajendra Nagar Campus - 1 Lucknow, India. Fifty-six schools representing Sri Lanka, India, Bangladesh, Nepal, Bhutan, Pakistan and Russia ...

Source:
http://news.google.com/news?q=biotechnology&output=rss

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

International Stem Cell Corporation and Subsidiaries (A Development Stage Company) Condensed Consolidated Statements of Financial Condition June 30, 2011 December 31, 2010 (Restated)(1) (Unaudited) Assets Cash and cash equivalents $ 3,581,933 $ 5,782,027 Accounts receivable 341,666 738,506 Inventory 1,329,433 856,083 Prepaid expenses and other current assets 290,196 228,338 Total current assets 5,543,228 7,604,954 Property and equipment, net 1,495,916 1,295,328 Patent licenses, net 1,056,562 986,714 Deposits and other assets 16,279 39,812 Total assets $ 8,111,985 $ 9,926,808 Liabilities and Stockholders' Equity Accounts payable $ 1,032,531 $ 582,824 Accrued expenses 855,315 545,781 Deferred revenue 137,834 759,667 Advances 250,000 250,000 Warrants to purchase common stock 1,027,171 2,399,605 Total current liabilities 3,302,851 4,537,877 Commitments and contingencies Stockholders' Equity Common stock, $.001 par value, 200,000,000 shares authorized, 76,599,928 shares and 74,771,107 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively 76,600 74,771 Convertible preferred stock, $.001 par value, 20,000,000 shares authorized, 2,800,043 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively 2,800 2,800 Subscription receivable on common stock - (4,875 ) Additional paid-in capital 59,780,363 56,170,006 Deficit accumulated during the development stage (55,050,629 ) (50,853,771 ) Total stockholders' equity 4,809,134 5,388,931 Total liabilities and stockholders' equity $ 8,111,985 $ 9,926,808 (1) The Company restated its financial statements for the year ended December 31, 2010, and the quarter ended March 31, 2011. International Stem Cell Corporation and Subsidiaries (A Development Stage Company) Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended June 30, Six Months Ended June 30, Inception (August 2001) through June 30, 2011 (Restated)(1) 2011 2010 (Restated)(1) 2011 (Restated)(1) 2010 (Restated)(1) Revenues Product sales $ 1,114,309 $ 441,118 $ 2,629,225 $ 713,744 $ 5,728,390 Royalties and license - - - - 135,000 Total revenue $ 1,114,309 $ 441,118 $ 2,629,225 $ 713,744 $ 5,863,390 Development expenses Cost of sales 362,131 214,330 791,125 360,706 2,506,597 Research and development 1,128,869 754,000 2,132,279 1,338,069 15,992,557 Marketing 345,800 291,576 664,006 424,994 3,063,155 General and administrative 2,135,732 2,033,615 4,368,470 3,408,821 27,692,292 Total development expenses 3,972,532 3,293,521 7,955,880 5,532,590 49,254,601 Loss from development activities (2,858,223 ) (2,852,403 ) (5,326,655 ) (4,818,846 ) (43,391,211 ) Other income (expense) Settlement with related company - - - - (92,613 ) Miscellaneous expense (12,040 ) (256 ) (11,140 ) (20,649 ) (28,652 ) Dividend income - 350 - 25,999 92,875 Interest expense - (6,805 ) - (14,079 ) (2,225,074 ) Sublease income 2,450 2,125 4,650 3,525 303,083 Change in market value of warrants 478,669 7,083,365 1,349,518 (1,347,960 ) (2,380,664 ) Total other income (expense) 469,079 7,078,779 1,343,028 (1,353,164 ) (4,331,045 ) Income (loss) before income taxes (2,389,144 ) 4,226,376 (3,983,627 ) (6,172,010 ) (47,722,256 ) Provision for income taxes - - - - 6,800 Net income (loss) $ (2,389,144 ) $ 4,226,376 $ (3,983,627 ) $ (6,172,010 ) $ (47,729,056 ) Dividends on preferred stock $ (107,203 ) $ - $ (213,231 ) $ (1,238,067 ) $ (7,751,380 ) Net income (loss) attributable to common stockholders $ (2,496,347 ) $ 4,226,376 $ (4,196,858 ) $ (7,410,077 ) $ (55,480,436 ) Basic earnings per common share $ (0.03 ) $ 0.06 $ (0.06 ) $ (0.11 ) Diluted earnings per common share $ (0.03 ) $ 0.04 $ (0.06 ) $ (0.11 ) Share used in per share calculations: Weighted average shares outstanding 76,340,016 68,676,504 75,842,071 64,789,250 Weighted average shares outstanding on a Fully Diluted Basis 76,340,016 114,797,830 75,842,071 64,789,250 (1) The Company restated its financial statements for the year ended December 31, 2010, and the quarter ended March 31, 2011. International Stem Cell Corporation Kenneth C. Aldrich, Chairman 760-940-6383 kaldrich@intlstemcell.com Or Ray Wood, CFO 760-940-6383 rwood@intlstemcell.com

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

Central Florida News 13

Cutting edge classes coming to one Tampa high school Central Florida News 13 (BN9 photo/Robert Hahn) Middleton High, a magnet school in Tampa, is offering courses in biomedical science and biotechnology to help prepare students for the 21st century. By Robert Hahn, Reporter An exciting new program is coming to Middleton High ...

Source:
http://news.google.com/news?q=biotechnology&output=rss

Since 2002, ESC therapy has treated over 10000 patients with degenerative diseases, injury and cancer, now it has move on to help people to delay ageing as disease usually comes from weaken and aged cells. ESC therapy provides young healthy cells to replace aged and mutated cells in order to prevent disease and delay ageing.

Read the original:
Embryonic stem cell therapy in China (www.esctherapy.com)

"Bone Marrow Stem Cells: Developing New Therapies in the Fight Against Disease"- Donald Kohn, January 18, 2011 Dr. Donald Kohn, UCLA professor of microbiology, immunology and molecular genetics, his research group at the Kohn Lab focus on developing new therapies for genetic diseases of the blood cells using gene therapy methods to correct hematopoietic stem cells. His laboratory performs studies on gene transfer, expression and immune response and then translates the findings into clinical trials.

View original post here:
"Bone Marrow Stem Cells" Donald Kohn